Literature DB >> 33185773

Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study.

Kenneth K C Man1,2, Shih-Chieh Shao3,4, Nathorn Chaiyakunapruk5,6, Piyameth Dilokthornsakul7, Kiyoshi Kubota8, Junqing Li9, Nobuhiro Ooba10, Nicole Pratt11, Anton Pottegård12, Lotte Rasmussen13, Elizabeth E Roughead11, Ju-Young Shin9, Chien-Chou Su3,13, Ian C K Wong1,2, Yea-Huei Kao Yang3, Edward Chia-Cheng Lai14,15.   

Abstract

It is known that younger patients treated with antipsychotics are at increased risk of metabolic events; however, it is unknown how this risk varies according to ethnicity, the class of antipsychotic and the specific product used, and by age group. We conducted a multinational sequence symmetry study in Asian populations (Hong Kong, Japan, Korea, Taiwan and Thailand) and non-Asian populations (Australia and Denmark) to evaluate the metabolic events associated with antipsychotics in both Asian and non-Asian populations, for typical and atypical antipsychotics, and by the subgroups of children and adolescents, and young adults. Patients aged 6-30 years newly initiating oral antipsychotic drugs were included. We defined a composite outcome for metabolic events which included dyslipidemia, hypertension and hyperglycemia. We calculated the sequence ratio (SR) by dividing the number of people for whom a medicine for one of the outcome events was initiated within a 12-month period after antipsychotic initiation by the number before antipsychotic initiation. This study included 346,904 antipsychotic initiators across seven countries. Antipsychotic use was associated with an increased risk of composite metabolic events with a pooled adjusted SR (ASR) of 1.22 (95% CI 1.00-1.50). Pooled ASRs were similar between Asian (ASR, 1.22; 95% CI 0.88-1.70) and non-Asian populations (ASR, 1.22; 95% CI 1.04-1.43). The pooled ASR for typical and atypical antipsychotics was 0.98 (95% CI 0.85-1.12) and 1.24 (95% CI 0.97-1.59), respectively. No difference was observed in the relative effect in children and adolescents compared to young adults. The risk of metabolic events associated with antipsychotics use was similar in magnitude in Asian and non-Asian populations despite the marked difference in drug utilization patterns.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antipsychotics; Metabolic events; Multi-national data; Pediatrics; Sequence symmetry analysis

Mesh:

Substances:

Year:  2020        PMID: 33185773     DOI: 10.1007/s00787-020-01674-6

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  40 in total

Review 1.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 2.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

Review 3.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics.

Authors:  C U Correll
Journal:  Eur Psychiatry       Date:  2010-06       Impact factor: 5.361

5.  Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups.

Authors:  Kim S J Lao; Anthony W Y Tam; Ian C K Wong; Frank M C Besag; Kenneth K C Man; Celine S L Chui; Esther W Chan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-06-30       Impact factor: 2.890

6.  International trends in antipsychotic use: A study in 16 countries, 2005-2014.

Authors:  Óskar Hálfdánarson; Helga Zoëga; Lise Aagaard; Miquel Bernardo; Lena Brandt; Anna Coma Fusté; Kari Furu; Kristina Garuoliené; Falk Hoffmann; Krista F Huybrechts; Luuk J Kalverdijk; Koji Kawakami; Helle Kieler; Takuya Kinoshita; Melisa Litchfield; Soffy C López; Jorge E Machado-Alba; Manuel E Machado-Duque; Mufaddal Mahesri; Prasad S Nishtala; Sallie-Anne Pearson; Johan Reutfors; Leena K Saastamoinen; Izumi Sato; Catharina C M Schuiling-Veninga; Yu-Chiau Shyu; Svetlana Skurtveit; Hélène Verdoux; Liang-Jen Wang; Corinne Zara Yahni; Christian J Bachmann
Journal:  Eur Neuropsychopharmacol       Date:  2017-07-27       Impact factor: 4.600

Review 7.  Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents.

Authors:  Sabine Mogwitz; Judith Buse; Nicole Wolff; Veit Roessner
Journal:  ACS Chem Neurosci       Date:  2018-03-16       Impact factor: 4.418

8.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors:  Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

Review 9.  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.

Authors:  H A Nasrallah
Journal:  Mol Psychiatry       Date:  2007-09-11       Impact factor: 15.992

10.  BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.

Authors:  Stephen J Cooper; Gavin P Reynolds; Tre Barnes; E England; P M Haddad; A Heald; Rig Holt; A Lingford-Hughes; D Osborn; O McGowan; M X Patel; C Paton; P Reid; D Shiers; J Smith
Journal:  J Psychopharmacol       Date:  2016-05-04       Impact factor: 4.153

View more
  1 in total

Review 1.  Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future.

Authors:  Sallie-Anne Pearson; Nicole Pratt; Juliana de Oliveira Costa; Helga Zoega; Tracey-Lea Laba; Christopher Etherton-Beer; Frank M Sanfilippo; Alice Morgan; Lisa Kalisch Ellett; Claudia Bruno; Erin Kelty; Maarten IJzerman; David B Preen; Claire M Vajdic; David Henry
Journal:  Int J Environ Res Public Health       Date:  2021-12-18       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.